EDIT vs NBIX · rev $32.3M vs P/E 45, rev $2.36B
Editas Medicine Inc (EDIT) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported NBIX revenue for 2024-12-31 was $2.36B. Net income was $341.3M. Revenue was up 24.8% from 2023-12-31 to 2024-12-31. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
EDIT currently screens at market cap $375.2M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the EDIT and NBIX stock pages for the full models.
Not investment advice.